<DOC>
<DOCNO>EP-0625163</DOCNO> 
<TEXT>
<INVENTION-TITLE>
PARATHYROID HORMONE FRAGMENTS, THEIR PREPARATION AND MEDICAMENTS CONTAINING THE SAME
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P1900	C07K14635	A61P4300	A61K3800	A61P300	A61P1910	C07K14435	C07K14575	A61K3822	A61P300	A61K3800	A61P4300	A61K3822	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	C07K	A61P	A61K	A61P	A61P	C07K	C07K	A61K	A61P	A61K	A61P	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P19	C07K14	A61P43	A61K38	A61P3	A61P19	C07K14	C07K14	A61K38	A61P3	A61K38	A61P43	A61K38	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
<APPLICANT-NAME>
BOEHRINGER MANNHEIM GMBH
</APPLICANT-NAME>
<APPLICANT-NAME>
ROCHE DIAGNOSTICS GMBH
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
DUVOS CHRISTIAN
</INVENTOR-NAME>
<INVENTOR-NAME>
MAYER HUBERT
</INVENTOR-NAME>
<INVENTOR-NAME>
MUELLER-BECKMANN BERND
</INVENTOR-NAME>
<INVENTOR-NAME>
STREIN KLAUS
</INVENTOR-NAME>
<INVENTOR-NAME>
WINGENDER EDGAR
</INVENTOR-NAME>
<INVENTOR-NAME>
DUVOS, CHRISTIAN
</INVENTOR-NAME>
<INVENTOR-NAME>
MAYER, HUBERT
</INVENTOR-NAME>
<INVENTOR-NAME>
MUELLER-BECKMANN, BERND
</INVENTOR-NAME>
<INVENTOR-NAME>
STREIN, KLAUS
</INVENTOR-NAME>
<INVENTOR-NAME>
WINGENDER, EDGAR
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Claims for the following Contracting States : BE, DE, DK, ES, FR, GB, GR, NL, SE
hPTH modifications selected from the group
consisting of PTH(2-35), PTH(2-36), PTH(3-35) and

PTH(3-36).
hPTH modifications according to claim 1,
characterised in that the PTH modifications are

PTH(2-35) or PTH(2-36).
hPTH modifications according to claim 1,
characterised in that the PTH modifications are

PTH(3-35) or PTH(3-36).
hPTH modifications according to one of claims
1 - 3, characterised in that the C-terminal carboxyl

group is amidated with a group Z and Z represents a
group of the formula -CONR
1
R
2
, whereby R
1
 and R
2
 are
the same or different and signify hydrogen or a

C
1
-C
6
-alkyl group.
hPTH modifications according to claim 4,
characterised in that the PTH modifications are

PTH(2-35)-Z, PTH(2-36)-Z, PTH(3-35)-Z or PTH(3-36)-Z.
Process for the preparation of hPTH modifications
according to one of claims 1 - 5, characterised in

that one prepares the fragments according to the solid
phase and liquid phase synthesis from partly blocked

amino acids contained in the fragments which are
coupled with one another in the sequence which

corresponds to the amino acids sequences in the
fragments.
Medicament containing hPTII modifications
according to one of claims 1 - 5 as active materials,

besides usual adjuvants and additive materials.
Medicament according to claim 7 with calcium-regulating
action. 
Use of hPTH modifications according to one of
claims 1 - 5 for the preparation of medicaments for

the regulation of the calcium level in the body or
fo
r the incorporation of calcium into the bones.
Claims for the following Contracting States : AT, CH, IE, IT, LI, LU, PT
hPTH modifications selected from the group
consisting of PTFI(1-35), PTH(1-36), PTH(2-35),

PTH(2-36), PTH(3-35) and PTH(3-36).
hPTH modifications according to claim 1,
characterised in that the PTH modification is PTH(1-35).
hPTH modifications according to claim 1,
characterised in that the PTH modification is PTH(1-36).
hPTH modifications according to claim 1,
characterised in that the PTH modifications are

PTH(2-35) or PTH(2-36).
hPTH modifications according to claim 1,
characterised in that the PTH modifications are

PTH(3-35) or PTH(3-36).
hPTH modifications according to one of claims
1 - 5, characterised in that the C-terminal carboxyl

group is amidated with a group Z and Z represents a
group of the formula -CONR
1
R
2
, whereby R
1
 and R
2
 are
the same or different and signify hydrogen or a C
1
-C
6
-alkyl
group.
hPTH modification according to claim 6,
characterised in that the PTH modifications are

PTH(1-35)-Z or PTH(1-36)-Z.
hPTH modifications according to claim 6,
characterised in that the PTH modifications are

PTH(2-35)-Z, PTH(2-36)-Z, PTH(3-35)-Z or PTH(3-36)-Z.
Process for the preparation of hPTH modifications
according to one of claims 1 - 8, characterised in

that one produces the fragments according to the
solid phase and liquid phase synthesis from partly

blocked amino acids contained in the fragments which
are coupled with one another in the sequence which 

corresponds to the amino acid sequences in the
fragments.
Medicaments containing hPTH modifications
according to one of claims 1 - 8 as active material,

besides usual adjuvant and additive materials.
Medicament according to claim 10 with calcium-regulating
action.
Use of hPTH modifications according to one of
claims 1 - 8 for the production of medicaments for

the regulation of the calcium level in the body or for
the incorporation of calcium into the bones.
</CLAIMS>
</TEXT>
</DOC>
